Cargando…

Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer

Lymphangioleiomyomatosis (LAM) is a rare cystic, destructive lung disease occurring almost exclusively in females. Bi-allelic inactivating tuberous sclerosis complex (TSC) gene mutations occur in LAM cells, resulting in activation of the mTORC1 pathway. Pivotal clinical trials have demonstrated that...

Descripción completa

Detalles Bibliográficos
Autores principales:	El-Chemaly, Souheil, Henske, Elizabeth P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2014
Materias:	Mini Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487253/ https://www.ncbi.nlm.nih.gov/pubmed/24591659 http://dx.doi.org/10.1183/09059180.00008813

Ejemplares similares

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
por: Courtwright, Andrew M., et al.
Publicado: (2017)

Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion
por: Esposito, Anthony J, et al.
Publicado: (2023)

Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis
por: Lamattina, Anthony M., et al.
Publicado: (2019)

Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis
por: Evans, Jilly F., et al.
Publicado: (2023)

Individualised patient profile: clinical utility of Flammer syndrome phenotype and general lessons for predictive, preventive and personalised medicine
por: Golubnitschaja, Olga, et al.
Publicado: (2018)

The lung microbiome in end-stage Lymphangioleiomyomatosis
por: Ng, Julie, et al.
Publicado: (2021)

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
por: Tang, Yan, et al.
Publicado: (2021)

Pathogenesis of pulmonary arterial hypertension: lessons from cancer
por: Guignabert, Christophe, et al.
Publicado: (2013)

Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M, et al.
Publicado: (2015)

Spatial Regulation of Exocytosis: Lessons from Yeast
por: Finger, Fern P., et al.
Publicado: (1998)

Lessons from mouse models of Graves’ disease
por: Eckstein, A., et al.
Publicado: (2020)

Lessons from Mice without Telomerase
por: Lansdorp, Peter M.
Publicado: (1997)

Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis
por: Kirkpatrick, Jesse D., et al.
Publicado: (2022)

Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014)

Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis
por: Qiu, Min, et al.
Publicado: (2022)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Inclusion body myositis – pathomechanism and lessons from genetics
por: Murnyák, Balázs, et al.
Publicado: (2015)

Treatment of Pain in Cancer: Towards Personalised Medicine
por: van den Beuken-van Everdingen, Marieke H. J., et al.
Publicado: (2018)

Cell wall integrity maintenance in plants: Lessons to be learned from yeast?
por: Hamann, Thorsten, et al.
Publicado: (2011)

Nutrition and immunity: lessons for COVID-19
por: Calder, Philip C.
Publicado: (2021)

Nutrition and immunity: lessons for COVID-19
por: Calder, Philip C.
Publicado: (2021)

Immunization against Viral Hepatitis B: Lessons Learnt from Kingdom of Cambodia
por: Sreng, Bun, et al.
Publicado: (2017)

Precision diabetes: Lessons learned from maturity‐onset diabetes of the young (MODY)
por: Tosur, Mustafa, et al.
Publicado: (2022)

Recent advances in the management of lymphangioleiomyomatosis
por: Xu, Kai-Feng, et al.
Publicado: (2018)

Lymphangioleiomyomatosis: a clinical review
por: O'Mahony, Anne M., et al.
Publicado: (2020)

Perspective: Towards Personalised Metabolic Coaching in Cancer
por: Van Soom *, T, et al.
Publicado: (2018)

Autoregulation of bacterial gene expression: lessons from the MazEF toxin–antitoxin system
por: Nikolic, Nela
Publicado: (2018)

Real-Time Monitoring of Tumorigenesis, Dissemination, & Drug Response in a Preclinical Model of Lymphangioleiomyomatosis/Tuberous Sclerosis Complex
por: Liu, Fangbing, et al.
Publicado: (2012)

Lymphangioleiomyomatosis (LAM)
Publicado: (2017)

Lymphangioleiomyomatosis: differential diagnosis and optimal management
por: Xu, Kai-Feng, et al.
Publicado: (2014)

Personalised neoantigen‐based therapy in colorectal cancer
por: Zhu, Ya‐Juan, et al.
Publicado: (2023)

CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis
por: Evans, Jilly Frances, et al.
Publicado: (2021)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate()
por: Kim, Hae-Suk, et al.
Publicado: (2014)

“T”eeing Up A Novel Therapy for Lymphangioleiomyomatosis
por: Wang, Xiaoyun, et al.
Publicado: (2020)

Human immunodeficiency virus (HIV) and coronavirus disease 2019; impact on vulnerable populations and harnessing lessons learnt from HIV programmes
por: Cordie, A., et al.
Publicado: (2021)

From lessons on the long‐term effects of the preimplantation environment on later health to a “modified ART‐DOHaD” animal model
por: Bari, Md Wasim, et al.
Publicado: (2022)

Delivering value‐based healthcare for people with diabetes in a national publicly funded health service: Lessons from Ireland and Wales
por: O’Donnell, Máire T, et al.
Publicado: (2023)

Hypertension management before and under the COVID-19 pandemic: lessons and future directions
por: Nozato, Yoichi, et al.
Publicado: (2023)

Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy
por: Poillet-Perez, Laura, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fqppqbdmq1263lt9nja96gfs0e